Viridian Therapeutics, Inc. ( VRDN ) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans November 9, 2026 8:00 AM EST Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radhika Tripuraneni - Chief Medical Officer Shan Wu - Chief Business Officer Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Thomas Smith - Leerink Partners LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Joseph Thome - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Dina Elmonshed - UBS Investment Bank, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Anish Nikhanj - Truist Securities, Inc., Research Division Qiu Wu - Goldman Sachs Group, Inc., Research Division John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics Conference Call.
